Analysts take a look at Acceleron Pharma Inc. (NASDAQ:XLRN) having this to say.

Acceleron Pharma Inc. (NASDAQ:XLRN) Logo
Investors sentiment decreased to 1.03 in Q3 2018. Its down 0.44, from 1.47 in 2018Q2. It is negative, as 20 investors sold Acceleron Pharma Inc. shares while 43 reduced holdings. 22 funds opened positions while 43 raised stakes. 42.72 million shares or 9.61% more from 38.98 million shares in 2018Q2 were reported.
Manufacturers Life Ins The stated it has 25,390 shares. Td Asset Incorporated holds 0.01% or 108,021 shares in its portfolio. Barclays Public Ltd Liability reported 27,183 shares. Citigroup has 7,548 shares. Northern Trust holds 0.01% or 464,680 shares. 1.53 million are owned by Perceptive Advisors Ltd. Great Point Prns Lc accumulated 917,767 shares. Morgan Stanley reported 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Synovus Corp invested in 59 shares or 0% of the stock. Putnam Invs Ltd Liability Corp holds 0.01% or 64,984 shares. Geode Mngmt Ltd Liability Corporation owns 420,942 shares. Quantbot Tech Lp reported 414 shares. Los Angeles Cap Management & Equity Research reported 15,080 shares. Proshare Limited Liability Corporation owns 23,495 shares or 0.01% of their US portfolio. Blackrock Incorporated holds 4.35 million shares.

Since August 30, 2018, it had 0 buys, and 6 insider sales for $2.18 million activity. On Thursday, January 3 the insider Dable Habib J sold $84,961. Another trade for 5,788 shares valued at $248,546 was sold by Kumar Ravindra. The insider MCLAUGHLIN KEVIN F sold 5,712 shares worth $244,494.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

Among 2 analysts covering Acceleron Pharma (NASDAQ:XLRN), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Acceleron Pharma had 2 analyst reports since September 10, 2018 according to SRatingsIntel. Morgan Stanley reinitiated it with “Equal-Weight” rating and $55 target in Monday, September 10 report. The firm earned “Overweight” rating on Tuesday, September 18 by PiperJaffray. Below is a list of Acceleron Pharma Inc. (NASDAQ:XLRN) latest ratings and price target changes.

18/09/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Overweight Old Target: $52 New Target: $75 Upgrade
10/09/2018 Broker: Morgan Stanley Rating: Equal-Weight New Target: $55 Reinitiate

The stock decreased 1.31% or $0.62 during the last trading session, reaching $46.31. About 55,394 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 37.04% since January 14, 2018 and is uptrending. It has outperformed by 37.04% the S&P500.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $2.14 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.